Cargando…

A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus

OBJECTIVES: Plasmacytoid dendritic cells (pDCs), through the production of type 1 interferons (IFNs) and other cytokines, are major contributors to systemic lupus erythematosus (SLE) pathogenesis. IL‐3 promotes pDC survival, but its role in SLE is not well characterised. This study investigated seru...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oon, Shereen, Monaghan, Katherine, Ng, Milica, Hoi, Alberta, Morand, Eric, Vairo, Gino, Maraskovsky, Eugene, Nash, Andrew D, Wicks, Ian P, Wilson, Nicholas J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928763/ https://www.ncbi.nlm.nih.gov/pubmed/31890206 http://dx.doi.org/10.1002/cti2.1097

Ejemplares similares

Machine learning applied to whole‐blood RNA‐sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus
por: Figgett, William A, et al.
Publicado: (2019)

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus
por: Godsell, Jack, et al.
Publicado: (2016)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses
por: Monaghan, Katherine A., et al.
Publicado: (2023)

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
por: Mende, Rachel, et al.
Publicado: (2018)

Clinical associations of serum interleukin-17 in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2013)

Clinical associations of cognitive dysfunction in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2023)

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway
por: Oon, Shereen, et al.
Publicado: (2016)

Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus
por: Northcott, Melissa, et al.
Publicado: (2022)

Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2018)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2016)

Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
por: Sreedharan, Sidha, et al.
Publicado: (2022)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
por: Croyle, Lucy, et al.
Publicado: (2015)

Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2022)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus
por: Nim, Hieu T., et al.
Publicado: (2019)

Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2019)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Editorial: Focus on Systemic Lupus Erythematosus
por: Harris, James, et al.
Publicado: (2016)

Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus
por: Chyuan, I-Tsu, et al.
Publicado: (2019)

IL-17 in Systemic Lupus Erythematosus
por: Crispín, José C., et al.
Publicado: (2010)

The performance of different classification criteria for systemic lupus erythematosus in a real-world rheumatology department
por: Tan, Brandon C H, et al.
Publicado: (2022)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

IL-10 revisited in systemic lupus erythematosus
por: Biswas, Swayanka, et al.
Publicado: (2022)

Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?
por: Boulos, Daniel, et al.
Publicado: (2017)

‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
por: Kandane-Rathnayake, Rangi, et al.
Publicado: (2022)

Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus
por: Cham, Candace M., et al.
Publicado: (2012)

MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus
por: Lang, Tali, et al.
Publicado: (2015)

Apolipoprotein C-III in patients with systemic lupus erythematosus
por: Martín-González, Candelaria, et al.
Publicado: (2022)

Anti-IL-10 antibody in systemic lupus erythematosus
por: Uchida, Marina, et al.
Publicado: (2019)

Asymptomatic Pulmonary Hypertension in Systemic Lupus Erythematosus
por: Kamel, Shereen R., et al.
Publicado: (2011)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile
Publicado: (1989)

The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus
por: Harley, Isaac T. W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1b9cj42re2dcrq1h6m32saodae